Merck stops study of HIV vaccine

Share this article:
A worldwide Phase II trial of a Merck HIV vaccine was halted after an independent reviewer found the vaccine ineffective, the firm said.

The trial of about 3,000 HIV-negative volunteers was being co-sponsored by Merck and the HIV Vaccine Trials Network (HVTN), the largest clinical trials program for developing and testing HIV vaccines which is part of the NIH.

Merck had been testing the drug for 10 years and, while the vaccine was not thought to have huge commercial potential, it was considered important in the global effort against the virus that causes AIDS. The best way to control the spread of the disease is thought to be through a prophylatic vaccine.

Had it worked, V520, as the vaccine was known internally, would have added to a string of R&D successes for Merck that also have included Gardasil, a vaccine against the virus that causes cervical cancer, and Januvia, a diabetes pill. Cordaptive, an extended-release niacin + flush inhibitor, was recently filed with the FDA.

“We share in the disappointment of the research and HIV communities today,” said Peter Kim, PhD, president, Merck Research Laboratories, in a statement. “Sadly, developing an effective AIDS vaccine remains one of the most challenging tasks facing modern medicine.”

According to Merck, the independent Data Safety Monitoring Board reviewed safety data and results of an interim efficacy analysis of the study, recommending discontinuation because the trial will not meet its efficacy endpoints.

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.